NL-OMON49285招募中不适用
Hospital Employees Response Ante COVID-19 Listed Early Symptoms (HERACLES): A clinical study to examine the dynamics of the host-response to viral infection including COVID-19 in healthcare workers - HERACLES
niversitair Medisch Centrum Utrecht0 个研究点目标入组 333 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 333
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adult healthcare workers who have signed informed consent form will be eligible
- •for inclusion. In order to be eligible to participate in this study, a subject
- •must meet all of the following criteria:
- •* No symptoms of acute respiratory tract infection at time of enrollment
- •* No symptoms of acute respiratory tract infection in the previous two weeks
- •* Risk of exposure to COVID-19 infected patients defined by daily bedside care
- •for patients
排除标准
- •A potential subject who meets the following criteria will be excluded from
- •participation in this study:
- •* An incute respiratory infection during the previous two weeks
- •* Previously proven COVID-19 infection
- •* A proven or suspected HIV, HBV, or HCV infection
- •* Active malignancy
- •* Current treatment with immune-suppresives or immune-modulation therapies
- •* Severe illnesses that affect life expectancy and quality of life (other than
- •suspected COVID-19 infection)
研究者
相似试验
进行中（未招募）
1 期
COVID-19 infections in hospital personnelEUCTR2021-004419-14-FITurku University Hospital1,000
尚未招募
不适用
Risk of infection with SARS-CoV-2 amongst physiciansCOVID-19NL-OMON21607Amsterdam University Medical Center, location AMC and University Medical Center Utrecht (UMCU)3,000
招募中
2 期
Caring for Healthcare ProfessionalsCTRI/2021/11/037970Ministry of Science Technology Department of Science Technology KIRAN Division
招募中
不适用
COVID-19 infections in health care workerscoronavirus infectionCOVID-19 infection10047438NL-OMON52573Medische MIcrobiologie & Infectiepreventie80
进行中（未招募）
1 期
Immune response to SARS-CoV-2 in health care workers, previously infected subjects, and immunocompromised subjects, before and after Covid-19 vaccination: a phase IV trialEUCTR2021-001769-19-SEGUVAX (Gothenburg University Vaccine Research Institute)1,200